Aurintricarboxylic acid
Based on 5 publication(s) in Google Scholar
Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 µM.
For research use only. We do not sell to patients.
- Purity: 92.0%
- CAS No.: 4431-00-9
- Formula: C22H14O9
- Molecular Weight:422.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Human Metabolite Library
HY-L123
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Ion Channel Compound Library
HY-L166
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Aurintricarboxylic acid
MoreAll P2X Receptor Isoforms
MoreAll Topoisomerase Isoforms
More
Biological Activity
|
Topoisomerase II |
p2x1 Receptor 8.6 nM (IC50) |
P2X3 Receptor 72.9 nM (IC50) |
Apoptosis |
miRNA 0.47 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
2.1 μg/mL
Compound: ATA
|
Inhibitory concentration for cytopathicity of HIV-1 (HTLV-IIIB) in CEM cells
Inhibitory concentration for cytopathicity of HIV-1 (HTLV-IIIB) in CEM cells
|
[PMID: 1704066] |
| HeLa | EC50 |
>76 μM
Compound: ATA
|
Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
|
[PMID: 17646410] |
| HeLa | EC50 |
0.076 μM
Compound: ATA
|
Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
|
[PMID: 17646410] |
| Huh-7 | IC50 |
31.6 mM
Compound: 36
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs
|
[PMID: 37216809] |
| Huh-7 | IC50 |
39.8 mM
Compound: 36
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs
|
[PMID: 37216809] |
| HuT78 | IC50 |
4 μg/mL
Compound: ATA
|
Compound was tested for reduce the number of gaint cells in HIV-1 infected HUT-78 cells cocultured with MOLT -4 cells
Compound was tested for reduce the number of gaint cells in HIV-1 infected HUT-78 cells cocultured with MOLT -4 cells
|
[PMID: 1704065] |
| HuT78 | IC50 |
4 μg/mL
Compound: ATA
|
Compound was tested for reduce the number of gaint cells in HIV-2 infected HUT-78 cells cocultured with MOLT -4 cells
Compound was tested for reduce the number of gaint cells in HIV-2 infected HUT-78 cells cocultured with MOLT -4 cells
|
[PMID: 1704065] |
| HuT78 | IC50 |
4 μg/mL
Compound: ATA
|
Inhibitory concentration that reduced the number of gaint cells by 50% between HIV-1 infected HUT-78 cells and uninfected MOLT-4 cells
Inhibitory concentration that reduced the number of gaint cells by 50% between HIV-1 infected HUT-78 cells and uninfected MOLT-4 cells
|
[PMID: 1704066] |
| HuT78 | IC50 |
4 μg/mL
Compound: ATA
|
Inhibitory concentration that reduced the number of gaint cells by 50% between HIV-2 infected HUT-78 cells and uninfected MOLT-4 cells
Inhibitory concentration that reduced the number of gaint cells by 50% between HIV-2 infected HUT-78 cells and uninfected MOLT-4 cells
|
[PMID: 1704066] |
| MT4 | IC50 |
280 μg/mL
Compound: ATA
|
Inhibitory concentration for cell viability in mock-infected MT-4 cells
Inhibitory concentration for cell viability in mock-infected MT-4 cells
|
[PMID: 1704065] |
| MT4 | CC50 |
280 μg/mL
Compound: ATA
|
50% cytotoxic concentrations for mock-infected MT-4 cells
50% cytotoxic concentrations for mock-infected MT-4 cells
|
[PMID: 1704066] |
| MT4 | IC50 |
0.85 μg/mL
Compound: ATA
|
Inhibitory concentration for cytopathicity of HIV-2 (LAV-2ROD) in MT-4 cells
Inhibitory concentration for cytopathicity of HIV-2 (LAV-2ROD) in MT-4 cells
|
[PMID: 1704066] |
| MT4 | IC50 |
1.1 μg/mL
Compound: ATA
|
Inhibitory concentration for cytopathicity of HIV-1 (HTLV-IIIB) in MT-4 cells
Inhibitory concentration for cytopathicity of HIV-1 (HTLV-IIIB) in MT-4 cells
|
[PMID: 1704066] |
Aurintricarboxylic acid weakly inhibits P2X2/3Rs, P2X2Rs, P2X4Rs or P2X7Rs[1].
?
Aurintricarboxylic acid inhibits ATP-induced currents in a concentration dependent manner[1].
?
Aurintricarboxylic acid can inhibit the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and vaccinia virus[2].
?
Aurintricarboxylic acid inhibits replication of influenza A and B viruses by inhibition of neuraminidase activities[2].
?
Aurintricarboxylic acid inhibits TWEAK-Fn14-mediated NF-κB activation[4].
?
Aurintricarboxylic acid (10 μM; 0.5-2 hours) suppresses TWEAK-Fn14-mediated NF-κB, Akt, and Src phosphorylation in GBM cells[4].
?
Aurintricarboxylic acid represses TWEAK-stimulated glioma cell migration and invasion without causing cell cytotoxicity[4].
?
Aurintricarboxylic acid (Compound 8) cannot regulate loading of endogenous let-7 onto AGO2 inside cultured cells, whereas can inhibit RISC loading of exogenous siRNA[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T98G, A172, GBM44 glioma cells
-
Concentration:10 μM
-
Incubation Time:0.5 hour, 1 hour, 2 hours
-
Result:Abrogated TWEAK activation of downstream signals including phosphorylation of the NF-κB family member p65, Akt, and Src in all three GBM cell lines.
Chemical Information
-
CAS No. 4431-00-9
-
Appearance Solid
-
Molecular Weight 422.34
-
Formula C22H14O9
-
Color Brown to black
-
SMILES
O=C(C=C/1)C(C(O)=O)=CC1=C(C2=CC(C(O)=O)=C(O)C=C2)\C3=CC(C(O)=O)=C(O)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
2026 May;27(5):1026-1038. PMID: 41974963 -
J Orthop Translat
The CD163/TWEAK/Fn14 axis: A potential therapeutic target for alleviating inflammatory bone loss. [Abstract]2024 Oct 4:49:82-95. PMID: 39430128 -
Cell Death Discov
ATP2B4 driven chromatin compaction exacerbates pancreatic cancer radiotherapy resistance. [Abstract]2026 May 25. PMID: 42185253 -
Cell Death Discov
Inhibition of TWEAK/Tnfrsf12a axis protects against acute liver failure by suppressing RIPK1-dependent apoptosis. [Abstract]2022 Jul 19;8(1):328. PMID: 35853848 -
Int Immunopharmacol
FN14 promotes ventilator-induced lung injury by regulating pyroptosis via the ANXA2/ERK1/2 axis. [Abstract]2025 Sep 23:162:114500. PMID: 40744784
Solvent & Solubility
DMSO : 125 mg/mL (295.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
NH4OH : 10 mg/mL (23.68 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Obrecht AS, et al. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors. Neuropharmacology. 2019 Nov 1;158:107749. [Content Brief]
[2]. Hashem AM, et al. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. PLoS One. 2009 Dec 17;4(12):e8350. [Content Brief]
[3]. Benchokroun Y, et al. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol. 1995 Jan 31;49(3):305-13. [Content Brief]
[4]. Alison Roos, et al. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 2017 Feb 14; 8(7): 12234–12246. [Content Brief]
[5]. Youtian Hu, et al. Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase. J Med Chem. 2019 Feb 14;62(3):1677-1683. [Content Brief]
[6]. Rengen Fan, et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 2019 Jun; 16(6): 707-718. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| NH4OH / DMSO | 1 mM | 2.3678 mL | 11.8388 mL | 23.6776 mL | 59.1940 mL |
| 5 mM | 0.4736 mL | 2.3678 mL | 4.7355 mL | 11.8388 mL | |
| 10 mM | 0.2368 mL | 1.1839 mL | 2.3678 mL | 5.9194 mL | |
| 15 mM | 0.1579 mL | 0.7893 mL | 1.5785 mL | 3.9463 mL | |
| 20 mM | 0.1184 mL | 0.5919 mL | 1.1839 mL | 2.9597 mL | |
| DMSO | 25 mM | 0.0947 mL | 0.4736 mL | 0.9471 mL | 2.3678 mL |
| 30 mM | 0.0789 mL | 0.3946 mL | 0.7893 mL | 1.9731 mL | |
| 40 mM | 0.0592 mL | 0.2960 mL | 0.5919 mL | 1.4799 mL | |
| 50 mM | 0.0474 mL | 0.2368 mL | 0.4736 mL | 1.1839 mL | |
| 60 mM | 0.0395 mL | 0.1973 mL | 0.3946 mL | 0.9866 mL | |
| 80 mM | 0.0296 mL | 0.1480 mL | 0.2960 mL | 0.7399 mL | |
| 100 mM | 0.0237 mL | 0.1184 mL | 0.2368 mL | 0.5919 mL |
Aurintricarboxylic acid Related Classifications
HY-122575 Related Classifications
Powered by Bioz